AstraZeneca PLC
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pascal Claude Roland Soriot
- Full Time Employees
- 94,300
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company dedicated to the discovery, development, production, and worldwide commercialization of innovative prescription medicines. The company maintains a comprehensive portfolio of treatments spanning key therapeutic areas, including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, rare disease, and vaccines and immune therapies. Its innovative products serve a global patient population, reaching over 125 countries through a network of local marketing companies, distributors, and representative offices. The firm's operational focus centers on pioneering scientific breakthroughs to address significant unmet medical needs. AstraZeneca actively invests in research and development, evidenced by substantial annual expenditures aimed at advancing a robust pipeline of next-generation therapies. Recent strategic initiatives include ambitious goals for revenue growth, with an aim to launch 20 new medicines and achieve $80 billion in total revenue by 2030. AstraZeneca consistently engages in strategic partnerships and acquisitions to bolster its capabilities and pipeline. Notable collaborations include an expanded alliance with Harbour BioMed for next-generation biotherapeutics and a research agreement with CSPC Pharmaceutical Group for novel oral drug candidates. The company also recently invested $2 billion in a new Maryland manufacturing facility to establish cell therapy platforms, and its digital health solutions arm, Evinova, was launched in late 2023. Recent product advancements and approvals include Koselugo for neurofibromatosis type 1 in adults and positive Phase III results for Baxdrostat in resistant hypertension. AstraZeneca was established through the merger of Astra AB and Zeneca Group in 1999, and its headquarters are situated in Cambridge, United Kingdom.
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
AstraZeneca PLC (AZN) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 76/100
Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance
Here's Why Astrazeneca (AZN) is a Strong Value Stock
AstraZeneca signs CSPC China deal for experimental kidney disease drugs
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
AZN vs. ILMN: Which Stock Should Value Investors Buy Now?
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
FTSE 100 Live: London stocks fall over 100 points in broad sell-off
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout
HIVE Digital Technologies upsizes convertible note offering to support GPU purchases, data center expansion
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note
The Healthcare M&A Wave
Ozempic Linked To Lower Risk Of Violence In New Study